Our Team
Executive Leadership
PreciseDx is led by the foremost experts in the use of artificial intelligence in systems pathology. The Company’s leaders have deep expertise in diagnostics, pathology, innovative technology, and business and are further supported by a world-renowned Clinical Advisory Board comprised of distinguished clinicians.
Eric is a Founding Board Member of PreciseDx and has stepped in as CEO to drive the execution of the commercialization process.
A global CEO and business builder driving shareholder value, he is frequently recruited by healthcare investors for CEO and Board roles to protect and drive their investments.
In Eric’s most recent role, he was CEO of AMRA Medical AB, a venture-funded (Pfizer Ventures, Novo Holdings) Software as a Medical Device (SaMD) company using AI/ML technology. AMRA services are based on MRIs with a global reference database for quantitative muscle and fat biomarker measurements for research, pharma, and providers.
Prior to AMRA, Eric was an Independent Consultant for Merck’s GHI (Global Health Innovation) Fund, where he conceived and drove a strategy to align Merck’s investment strategy with their commercial requirements across three major divisions to ensure profitable investments and successful corporate collaborations.
Previously, Eric was CEO and Board Member for VirtualScopics, a publicly traded (NASDAQ: VSCP) imaging Contract Research Organization sold to BioTelemetry (NASDAQ: BEAT) in 2016, which is currently part of ICON plc. Specifically recruited by Merck, he redefined the research services offering, established an FDA regulatory-compliant structure, and drove sales from $7.5 million to $30 million, enabling the company to sell to BioTelemetry.
Eric earned a BA in General Business Administration from Michigan State University. He studied the European Union at the Erasmus University in Rotterdam, the Netherlands.
Dr. Fernandez is a co-founder and currently Chief Scientific Officer of PreciseDx, in addition to his position as Adjunct Associate Professor in the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at the Mount Sinai Health System. He received his medical degree from Drexel University College of Medicine and completed his residency in anatomic and clinical pathology as well as fellowships in surgical pathology and cytopathology from New York University School of Medicine.
Dr. Fernandez has spent the last seven years as Associate Professor at Mount Sinai building and developing the PreciseDx team and platform. Before that, he was in industry as the Medical Director for Roche Tissue Diagnostics’ (Ventana) Digital Pathology group, Vice President for Pathology and Research and Development at Aureon Biosciences, and a Staff Pathologist at Genzyme Genetics, where he specialized in oncologic pathology and tissue biomarkers.
Ed Sitar is an experienced financial executive with an extensive healthcare background. He has lead both public and private companies, raising substantial capital and improving operations. Mr. Sitar’s previous roles include serving as the Chief Financial Officer of Variantyx, Inc, 9 Meters Biopharma (Nasdaq:NMTR) and Cancer Genetics, Inc. (Nasdaq:CGIX). Mr. Sitar holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey.
Dr. Donovan is a co-founder of PreciseDx, and currently serves as Vice-chair and Professor of Translational Research in the Department of Pathology at the University of Miami. In addition to a previous academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years of experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals.
Most recently, he has served as Chief Medical Officer of Renalytix, Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc., and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan earned his Bachelor of Science degree in Zoology, a Master of Science degree in Endocrinology, and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his medical degree from the Rutgers New Jersey Medical School.
Dr. Cordon-Cardo is a co-founder and Chairman of the Advisory Board of PreciseDx, and currently serves as Professor and Chair System-Wide of the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai Health System. From 1987 to 2006 Dr. Cordon-Cardo was a faculty member in the Department of Pathology at Memorial Sloan-Kettering Cancer Center, where he created the Division of Molecular Pathology and served as its first Director; scaling the academic ranks from Assistant to Professor of Pathology at Weill Cornell Medical College, Cornell University.
A pioneer of the oncologic molecular pathology discipline, Dr. Cordon-Cardo has helped establish a deeper understanding of the mechanisms of human cancers and new targets for cancer therapeutics, enhancing the vision of personalized medicine. Dr. Cordon-Cardo earned his medical degree from the Autonomous University of Barcelona (1980), and his Ph.D. in Cell Biology and Genetics from Cornell University (1985).
Ted M. Diehl is Vice President of Commercial Development at PreciseDx. Diehl is a highly accomplished oncology executive with over 20 years of leadership experience in business development, commercialization, and revenue generation. Prior to joining PreciseDx, Diehl held various executive positions at Massive Bio in New York City, Sema4, IBM Watson Healthcare, Genomic Health, Inc., Sanofi, and TAP Pharmaceutical Products Inc. Diehl graduated from Immaculata University with a Bachelor of Arts in Human Resource Management and in Organizational Dynamics and is earning his masters in Executive Leadership from Liberty University. Additionally, he obtains an annual Oncology/Biotechnology Certification through the NCCN Academy and is a Certified Medical Representative through the CMR Institute, University of Medicine and Dentistry of New Jersey. Through his experience, Diehl has been successful in pioneering oncology market entry for both molecular diagnostic testing and AI utility. His expertise encompasses overcoming the challenges of introducing innovative technologies and creating collaborations between commercial and scientific teams to implement strategies for both commercial success and clinical standards of care.
Clinical Advisory Board
Dr. Cordon-Cardo is Professor and Chair System-Wide of the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai Health System. He was previously Professor and Vice-Chair of Pathology at Columbia University. From 1987 to 2006 Dr. Cordon-Cardo was a faculty member in the Department of Pathology at Memorial Sloan-Kettering Cancer Center, where he created the Division of Molecular Pathology and served as its first Director; scaling the academic ranks from Assistant to Professor of Pathology at Weill Cornell Medical College, Cornell University.
A pioneer of the oncologic molecular pathology discipline, Dr. Cordon-Cardo has helped establish a deeper understanding of the mechanisms of human cancers and new targets for cancer therapeutics, enhancing the vision of personalized medicine. Dr. Cordon-Cardo earned his medical degree from the Autonomous University of Barcelona (1980), and his PhD in Cell Biology and Genetics from Cornell University (1985).